Partner David Rosen was quoted in a Newsweek article published on May 1, 2014, titled “Be Still, My Bioficial Heart.” The article explained the benefits and challenges of creating a “bioficial heart,” which researchers at the University of Louisville recently announced could be developed using living cells from a potential transplant patient combined with artificial materials to create a fully functional 3-D printed heart. Given that the U.S. Food and Drug Administration (FDA) is many years out from approving lab-built organs for patients, Rosen said, “The potential challenges include demonstrating that the organs will function as predicted, demonstrating the sustainability of these organs once transplanted and obtaining approval to test and market these from [the] FDA.”
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”